By Jordan Davidson
Originally published by our sister publication, Pain Medicine News
A study has used a novel approach to treat neuropathic pain effectively with monoclonal antibodies that block calcitonin gene–related peptide (CGRP). The promising results, which showed a nearly 42% decrease on the Neuropathy Pain Scale (NPS) at 12 months after treatment, potentially pave the way for future randomized controlled trials to determine the efficacy of anti-CGRP monoclonal antibodies as a